Atomoxetine Hydrochloride + Sertraline + Placebo
ApprovedCompleted 0 watching 0 views this week๐ฅ Hot
85
Development Stage
โ
Pre-clinicalโ
Phase 1โ
Phase 2โ
Phase 35
ApprovedIndication / Disease
Depressive Symptoms
Conditions
Depressive Symptoms
Trial Timeline
Jun 1, 2003 โ Jan 1, 2005
NCT ID
NCT00485862About Atomoxetine Hydrochloride + Sertraline + Placebo
Atomoxetine Hydrochloride + Sertraline + Placebo is a approved stage product being developed by Eli Lilly for Depressive Symptoms. The current trial status is completed. This product is registered under clinical trial identifier NCT00485862. Target conditions include Depressive Symptoms.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00485862 | Approved | Completed |
Competing Products
20 competing products in Depressive Symptoms
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| duloxetine | Eli Lilly | Pre-clinical | 23 |
| Duloxetine Hydrochloride | Eli Lilly | Pre-clinical | 23 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| LY2216684 | Eli Lilly | Phase 1 | 33 |
| Duloxetine | Eli Lilly | Phase 3 | 77 |
| LY2216684 + Digoxin | Eli Lilly | Phase 1 | 33 |
| Duloxetine + Paroxetine | Eli Lilly | Phase 3 | 77 |
| Duloxetine + placebo | Eli Lilly | Phase 3 | 77 |
| LY2216684 + Placebo + Escitalopram | Eli Lilly | Phase 2 | 52 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| quetiapine extended release (XR) + Placebo | Astellas Pharma | Phase 2 | 52 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| FK949E | Astellas Pharma | Phase 1 | 33 |
| Mirtazapine Tablets | Sun Pharmaceutical | Approved | 85 |
| Duloxetine Hydrochloride | Shionogi | Phase 3 | 77 |
| Duloxetine Hydrochloride + Placebo | Shionogi | Phase 3 | 77 |
| ONO-2333Ms Experimental 2 + Placebo + ONO-2333Ms Experimental 1 | Ono Pharmaceutical | Phase 2 | 52 |
| ONO-1110 + Placebo | Ono Pharmaceutical | Phase 2 | 52 |
| Pramipexole ER + Escitalopram | Cipla | Phase 2 | 52 |